VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a mixed sentiment. Positive factors include significant revenue growth and reduced operating expenses, but concerns arise from high cash burn and regulatory uncertainties. The Q&A revealed management's optimism about future milestones and automation, yet lacked clarity on certain operational details. Overall, the financial performance and optimistic guidance balance out the risks and uncertainties, leading to a neutral stock price prediction.
Key Financial Performance
Revenue $1.2 million, a growth of 59% over the full year 2023.
Nu.Q Vet Cancer Test Revenue $0.8 million, grew by 75% over the prior year.
Nu.Q Discover Revenue $0.4 million, with year-on-year growth of 40%.
Operating Expenses 23% lower compared to the full year 2023, with second-half operating expenses down 31%.
Net Cash Used in Operating Activities $25.9 million in 2024, compared with $18.1 million in 2023, which benefited from $13 million in milestone payments from Heska.
Cash and Cash Equivalents Approximately $3.3 million at the end of the year.
Non-Dilutive Funding Received approximately $1.8 million in non-dilutive funding payments from agencies in Belgium.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nu.Q Vet Cancer Test: Expanded access to the Nu.Q Vet Cancer Test across more than 20 countries, sold approximately 120,000 tests in 2024, resulting in a 75% increase in vet revenue compared to 2023.
Nu.Q Discover: Generated approximately $400,000 in revenue in 2024, with over 2,600 samples processed for 13 customers, including 6 pharmaceutical companies.
Nu.Q NETs: Recorded first revenue for Nu.Q NET, marking a significant milestone.
Market Expansion: Nu.Q Vet Cancer Test is now available in over 20 countries, with significant market penetration achieved in Canada, Australia, New Zealand, the U.K., and Japan.
Licensing Agreements: Strong interest in potential out-licensing and/or supply agreements for Nu.Q NETs and oncology portfolio, with ongoing discussions with multiple large companies.
Revenue Growth: Total revenue increased by 59% year-on-year to $1.2 million, with Nu.Q Vet revenue growing by 75%.
Cost Reduction: Operating expenses were reduced by 23% compared to 2023, with second-half expenses down 31%.
Strategic Focus: Aim to sign multiple licensing deals in human diagnostics in 2025, leveraging insights from veterinary licensing negotiations.
Clinical Applications: Nu.Q platform is being positioned for use in regular clinical settings for oncology and NETosis, with CE Marked Nu.Q NETs test purchased by 3 centers of excellence in Europe.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The company faces uncertainties related to regulatory approvals for its Nu.Q platform in human diagnostics, which could impact the timeline for commercialization.
Competitive Pressures: VolitionRx is operating in a highly competitive market for diagnostic screening and liquid biopsy, which may affect its ability to secure licensing deals and market share.
Supply Chain Challenges: The company has identified the need to automate its testing processes to scale operations, indicating potential supply chain challenges in meeting increasing demand.
Economic Factors: The company noted that revenues remain 'lumpy and difficult to predict,' which could be influenced by broader economic conditions affecting healthcare spending.
Funding Risks: While the company has received non-dilutive funding, reliance on such funding sources poses a risk if future grants or financial support are not secured.
Operational Costs: Despite reducing operating expenses, the company reported a significant cash burn of $25.9 million in 2024, raising concerns about financial sustainability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Licensing Deals: In 2025, VolitionRx aims to sign multiple licensing deals in humans, with strong interest from large companies for both Nu.Q NETs and oncology portfolio.
Revenue Growth: VolitionRx recorded $1.2 million in revenue for 2024, a growth of 59% over 2023, with Nu.Q Vet Cancer Test revenue at $0.8 million, growing by 75%.
Cost Management: Operating expenses were reduced by 23% in 2024 compared to 2023, with a 31% reduction in the second half of 2024.
Cash Neutrality: One of the key financial goals for 2025 is to achieve cash neutrality, meaning income matches expenditure on a cash basis.
Market Expansion: The Nu.Q Vet Cancer Test is now available in over 20 countries, with significant market penetration and ongoing supply agreements.
Clinical Validation: A final validation study for Nu.Q Cancer is underway in Taiwan, with potential inclusion in the national screening program if successful.
Revenue Guidance: VolitionRx will not provide revenue guidance for 2025 at this point due to the unpredictable nature of early-stage commercialization.
Future Revenue Expectations: The company anticipates significant revenue generation from the first human clinical study utilizing Nu.Q Discover biomarkers.
Financial Projections: Cash and cash equivalents at the end of 2024 totaled approximately $3.3 million, with ongoing discussions for additional funding.
Milestone Payments: VolitionRx has received milestone payments of $23 million from previous agreements, contributing to ongoing revenue streams.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Milestone Payments: Received milestone payments of $23 million in addition to ongoing revenue from every test sold.
Cash and Cash Equivalents: Cash and cash equivalents at the end of the year totaled approximately $3.3 million.
Revenue Growth: Revenue was up 59% year-on-year, with Nu.Q Vet Cancer Test revenue growing by 75%.
Operating Expenses: Operating expenses were down 23% on a full-year basis.
Non-Dilutive Funding: Received approximately $1.8 million in non-dilutive funding payments from agencies in Belgium.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:I wanted to just check on the Heska feline cancer testing program. Is that something that could happen imminently? Or is it a project that's taking a little bit of time?
A:We've done a lot of work on the feline side... we expect to have that completed later this year.
Q:So you could get that milestone payment later this year?
A:That's correct.
Q:Have you had any discussions with them about how this test might be employed in a screening regimen or how it might be used in practice?
A:Yes, they are very excited... there is potential for crosstalk and validation of both those results.
Q:Could you elaborate on the key drivers behind the quarterly sales trends and share some high-level outlook on the factors that may state that sales performance in 2025?
A:What we saw in 2024 was that the largest of our company customers tended to buy stock in blocks or batches... In 2025, we'll see automation in the central labs launching.
Q:Could you please share your approach to managing any time and risks associated with securing new financing?
A:We have reduced the cash burn coming into the year... until then, we'll keep a very tight grip on the expenses and the cash flows.
Q:How many data rooms do you have? Where are they? And what's been the tenor of activities when you go to a conference?
A:We have a data room for both oncology and NETosis... the more data you have, you can keep updating them with all the processes.
Q:Can you give us an idea of what the average contract is now?
A:The smaller contracts... usually want you to run samples as a sort of proof of concept... the next step beyond that is up to $500,000 or more.
Q:Could you just add a little color or expand on the validation study, this new 500-patient study that's happening at the National Taiwan University Hospital?
A:It's going very well... we could have interim data this year, really supporting that and would expect to be finished by the end of the year.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specifics of the screening regimen implementation and the exact number of data rooms, as well as the average contract values, using vague language and lacking detailed figures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Antech
Belgium
Cancer Congress
Chief Medical
Fuji
Medical Officer
Nu NET
Nu pillar
Nu test
Phase
aim
assay
basis
biomarkers
clinician
deal
development
diagnosis treatment
drug
enrichment
et al
evidence
expertise
industry
licensing partner
marker
nucleosome
patient risk
patient study
pharmaceutical company
physician
pillar Nu
portfolio
rate
research
response
role
screening
study Nu
tool
trimethyl
use Nu
vet
VNRX Transcript
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call summary shows positive financial metrics such as a 25% revenue increase and improved net loss, gross margin, and cash flow. However, the absence of strategic initiatives, operational updates, and return discussions, coupled with the acknowledgment of risks in forward-looking statements, balances the sentiment. Without additional insights from the Q&A section, the sentiment remains neutral, lacking strong catalysts for significant stock price movement.
VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript
Positive4-1
The earnings call reveals a strong financial performance with significant revenue growth and reduced expenses, indicating improved operational efficiency. Despite uncertainties in licensing agreements and future funding, the company has secured substantial nondilutive funding, mitigating immediate financial concerns. The Q&A indicates potential for growth through partnerships and global expansion, though management's lack of specific guidance introduces some uncertainty. Overall, the company's strategic developments and financial improvements suggest a positive outlook for the stock price in the short term.
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript
Positive8-15
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
VNRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
